Clinical Trial Update: Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating intranasal bevacizumab for nasal telangiectasia in hereditary hemorrhagic telangiectasia to identify an effective dose.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: University Hospital, Caen | Conditions: Telangiectasia, Hereditary Hemorrhagic | Phase 1, Phase 2 | Status: COMPLETED